Advertisement
ResearchIn-Press PreviewCell biologyOncology
Open Access |
10.1172/JCI198580
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Huang, C. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Rui, R. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Guo, H. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by He, A. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Gao, W. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Fan, J. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Zhang, C. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Gong, Y. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Zhou, L. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by Li, X. in: PubMed | Google Scholar
1Department of Urology, Peking University First Hospital, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
2Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China
Find articles by He, S. in: PubMed | Google Scholar
Published November 19, 2026 - More info
Despite recent therapeutic advances, the prognosis of patients with metastatic clear cell renal cell carcinoma (ccRCC) remains poor, and the molecular mechanisms driving metastasis are not fully understood. Herein, we identify forkhead box transcription factor A2 (FOXA2) as a key regulator of ccRCC metastasis. FOXA2 expression is elevated in metastatic ccRCC and correlates with adverse clinical outcomes. Functional assays show that FOXA2 enhances ccRCC cell invasion and metastasis both in vitro and in vivo. Mechanistically, FOXA2 recruits the histone acetyltransferase HAT1 as a transcriptional coactivator to upregulate growth differentiation factor 15 (GDF15) expression, which in turn activates GFRAL/RET-mediated STAT3 signaling and the epithelial-to-mesenchymal transition (EMT), thereby driving metastasis through both autocrine and paracrine pathways. Moreover, tumor cell-secreted GDF15 facilitates CD8+ T cell exhaustion within the tumor microenvironment, contributing to immune evasion and resistance to anti-PD-1 therapy. Importantly, pharmacologic inhibition of this pathway using either the GDF15-neutralizing antibody ponsegromab or the RET inhibitor pralsetinib markedly impairs FOXA2-driven metastasis and synergizes with anti-PD-1 therapy. Together, our findings delineate a FOXA2–GDF15–STAT3 signaling axis that orchestrates metastatic progression and immune suppression in ccRCC and suggest promising therapeutic strategies for patients with advanced disease.